• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2023 Fiscal Year Final Research Report

Elucidation of the molecular pathogenesis of lymphoma with a focus on PVT1 RNA and its application to novel targeted therapy

Research Project

  • PDF
Project/Area Number 21K15579
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionAichi Medical University

Principal Investigator

Mizuno Shohei  愛知医科大学, 医学部, 准教授 (70556638)

Project Period (FY) 2021-04-01 – 2024-03-31
Keywordsびまん性大細胞性B細胞リンパ腫 / PVT1 / long non-coding遺伝子 / 8q24
Outline of Final Research Achievements

To elucidate the role of PVT1 in lymphoma pathogenesis and its relevance to drug resistance and prognosis, we conducted this study. We observed a trend toward increased expression of PVT1 and cyclic PVT1 in a group of EZH2-positive diffuse large B-cell lymphoma (DLBCL) cells. Furthermore, by knocking down MYC, PVT1 and cyclic PVT1 in DLBCL cell lines, we are invesitigating that MYC and cyclic PVT1 contribute to increased cell proliferation and decreased sensitivity to each drug in R-CHOP therapy.

Free Research Field

血液造血器腫瘍

Academic Significance and Societal Importance of the Research Achievements

リンパ腫の中で、びまん性大細胞性B細胞リンパ腫(DLBCL)が30%以上と最も多くを占める。DLBCL 患者の10%程度が初回治療抵抗性となり、さらに25%程度が再発するとされている。さらに、再発、治療抵抗性DLBCLの予後は、生存期間中央値 6.3 ヶ月、2 年生存率20%と極めて不良である。本研究結果はPVT1が一部のDLBCLの難治性や薬剤耐性に影響することを解明する一助になりうるものと考えられる。今後はDLBCLの難治性や薬剤耐性の問題を克服するため、PVT1と治療についてさらなる研究が必要である。

URL: 

Published: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi